logo
  

DuPont Says Plans To Defend Against EU's Allegations On HFO-1234yf

Chemical company EI DuPont De Nemours & Co. (DD) said that it has complied at all times with applicable laws in its development and commercialization of HFO-1234yf, and it plans to defend vigorously against the European Commission's allegations and preliminary conclusions. This is one step in a long process, and while it may take years to be resolved, the company is confident that the Commission will ultimately conclude that actions taken by DuPont complied with applicable laws. It will fight this every step of the way, as it has no basis in law or fact.

Thierry Vanlancker, president, DuPont Chemicals & Fluoroproducts, issued the statement about the European Commission's Statement of Objections.

Thierry said, "Without DuPont and Honeywell's joint development, HFO-1234yf would not have been successfully developed and brought to market, and there would today be no commercially available solution satisfying the MAC Directive's criteria......We have endured a host of regulatory, technical and financial challenges to be able to proudly offer this product to our customers, and we are disappointed the Commission chose to file this Statement in the final days of this Commissioner's tenure, after having looked at these facts for multiple years."

The company said it will respond to the Statement and will work to ensure that the Commission understands the competitive landscape and the details of our competitive relationship with Honeywell.

Regardless of the Statement, the EU MAC Directive remains in full force today, with all new vehicles required to use a refrigerant with a GWP of under 150 by January 2017.

DuPont noted that it remains committed to work with its customers to ensure it meets their demand needs as they prepare to comply with the MAC Directive and other global programs that are driving mobile air conditioning to low GWP options.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT